Once again I'd be willing to bet this will never see human testing in our lifetime because we have NO strategy or stroke leadership.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=159323&CultureCode=en
Hendrik Jan Ankersmit’s research group at the Clinical Department of
Thoracic Surgery of MedUni Vienna has successfully shown that irradiated
white blood cells release substances that reduce the severity of the
damage caused by a heart attack or stroke and in spinal injuries and
have a positive effect upon tissue repair. However, up until now it
wasn't known exactly which particular substances were responsible for
these beneficial effects. This has now been discovered.
The
study, which was conducted under the direction of Ankersmit and Michael
Mildner (University Department of Dermatology of MedUni Vienna) as part
of the doctoral thesis of Lucien Beer, an MDPhD student and assistant
doctor at the University Department of Radiology and Nuclear Medicine of
MedUni Vienna, has now been published in the journal "Scientific
Reports", a magazine from Nature Publishing Group.
The main finding of the study: "A purified exosome or protein
fraction is responsible for these beneficial effects," explains
Ankersmit. Apart from these protein complexes, lipids (fat-like
substances) and other micro-particles are also involved. Ionising
radiation stimulates the release of more of this cocktail and also
enables us to regulate the quality of the substances it contains. In
this way, white blood cells can act as "bioreactors" for producing these
substances, known as APOSEC (a contraction of APOptotic SECretome).
These bioreactors are easy to extract and the effort involved is
comparable with that of conventional blood donation.
The
researchers use human virus-inactivated APOSEC (Linz Blood Donation
Centre, Prim. Gabriel), which the Austrian Food Safety Agency (AGES) has
approved for use in clinical trials on humans and which is very similar
to the test product approved by the AGES.[U1] It was shown in the
large animal model (in collaboration with Mariann Gyöngyösi of the
Cardiology Department of MedUni Vienna) that heart attack damage can be
significantly reduced. Ankersmit: "These positive findings give us
legitimate hope for the planned studies in the areas of human
dermatology and cardiology."
Clinically relevant: the first
regeneration study using APOSEC on human skin wounds was successfully
completed in autumn 2015. This study was financed by the Christian
Doppler Research Association (For information go to:
https://clinicaltrials.gov/ct2/show/NCT02284360?term=NCT02284360&rank=1).
http://www.meduniwien.ac.at
No comments:
Post a Comment